Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 15, 2022

SELL
$75.79 - $100.07 $526,816 - $695,586
-6,951 Closed
0 $0
Q1 2022

May 16, 2022

BUY
$72.45 - $94.81 $313,780 - $410,622
4,331 Added 165.31%
6,951 $652,000
Q4 2021

Feb 14, 2022

BUY
$79.65 - $106.22 $208,683 - $278,296
2,620 New
2,620 $223,000
Q3 2021

Nov 15, 2021

SELL
$86.18 - $99.03 $1.54 Million - $1.77 Million
-17,877 Closed
0 $0
Q2 2021

Aug 16, 2021

BUY
$89.43 - $102.27 $1.6 Million - $1.83 Million
17,877 New
17,877 $1.74 Million
Q1 2021

May 17, 2021

SELL
$87.57 - $119.4 $709,929 - $967,975
-8,107 Closed
0 $0
Q4 2020

Feb 16, 2021

SELL
$86.91 - $108.33 $545,881 - $680,420
-6,281 Reduced 43.65%
8,107 $777,000
Q3 2020

Nov 16, 2020

BUY
$96.16 - $135.15 $1.38 Million - $1.94 Million
14,388 New
14,388 $1.38 Million
Q2 2020

Aug 14, 2020

SELL
$85.09 - $130.36 $37,950 - $58,140
-446 Closed
0 $0
Q1 2020

May 15, 2020

SELL
$75.11 - $113.76 $154,426 - $233,890
-2,056 Reduced 82.17%
446 $39,000
Q4 2019

Feb 14, 2020

BUY
$86.8 - $118.57 $47,392 - $64,739
546 Added 27.91%
2,502 $269,000
Q3 2019

Nov 14, 2019

BUY
$83.82 - $101.5 $163,951 - $198,534
1,956 New
1,956 $176,000
Q2 2019

Aug 14, 2019

SELL
$72.24 - $91.27 $103,592 - $130,881
-1,434 Closed
0 $0
Q1 2019

May 15, 2019

BUY
$69.31 - $91.53 $99,390 - $131,254
1,434 New
1,434 $126,000
Q4 2018

Feb 14, 2019

SELL
$68.32 - $124.36 $33,613 - $61,185
-492 Closed
0 $0
Q3 2018

Nov 14, 2018

BUY
$98.88 - $125.85 $48,648 - $61,918
492 New
492 $60,000
Q2 2018

Aug 14, 2018

SELL
$75.3 - $105.99 $17,544 - $24,695
-233 Closed
0 $0
Q1 2018

May 15, 2018

BUY
$75.88 - $92.43 $17,680 - $21,536
233 New
233 $19,000

Others Institutions Holding NBIX

About NEUROCRINE BIOSCIENCES INC


  • Ticker NBIX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 95,639,296
  • Market Cap $11.4B
  • Description
  • Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...
More about NBIX
Track This Portfolio

Track Point72 Hong Kong LTD Portfolio

Follow Point72 Hong Kong LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Point72 Hong Kong LTD, based on Form 13F filings with the SEC.

News

Stay updated on Point72 Hong Kong LTD with notifications on news.